Alexion Pharmaceuticals $ALXN announced that it has initiated pivotal clinical studies for simultaneous registration trials to support regulatory applications for ALXN1210, the next-generation treatment intended to replace Soliris (eculizumab) for curing paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).